Log in
NASDAQ:ICAD

iCAD Stock Forecast, Price & News

$9.76
-0.14 (-1.41 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.62
Now: $9.76
$10.03
50-Day Range
$8.56
MA: $9.79
$11.60
52-Week Range
$5.91
Now: $9.76
$15.31
Volume137,805 shs
Average Volume281,228 shs
Market Capitalization$223.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which offers automated, consistent, and standardized reporting tool used for mammogram. It also provides ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound Panorama, a prototype software product for determining risk factors in interval cancers; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200
Employees135

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share

Profitability

Net Income$-13,550,000.00

Miscellaneous

Market Cap$223.51 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$9.76
-0.14 (-1.41 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











iCAD (NASDAQ:ICAD) Frequently Asked Questions

How has iCAD's stock price been impacted by Coronavirus (COVID-19)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICAD shares have decreased by 12.2% and is now trading at $9.76.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of iCAD?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for iCAD
.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for iCAD
.

How can I listen to iCAD's earnings call?

iCAD will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) posted its quarterly earnings data on Tuesday, August, 4th. The technology company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.04. The technology company earned $5.57 million during the quarter. iCAD had a negative net margin of 69.88% and a negative return on equity of 75.69%.
View iCAD's earnings history
.

What price target have analysts set for ICAD?

4 brokers have issued 12 month target prices for iCAD's shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate iCAD's share price to reach $13.50 in the next year. This suggests a possible upside of 38.3% from the stock's current price.
View analysts' price targets for iCAD
.

Are investors shorting iCAD?

iCAD saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 932,700 shares, a decline of 15.2% from the September 30th total of 1,100,000 shares. Based on an average daily volume of 193,200 shares, the days-to-cover ratio is presently 4.8 days.
View iCAD's Short Interest
.

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 66, Pay $495.37k)
  • Ms. Stacey M. Stevens, Pres (Age 52, Pay $514.82k)
  • Mr. Jonathan Go, Chief Technology Officer (Age 57, Pay $460.85k)
  • Mr. Richard Scott Areglado, Chief Financial Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 63)
  • Mr. Jeffrey Sirek, Sr. VP & Gen. Mang. of Xoft

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by a variety of retail and institutional investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.14%), Cadence Capital Management LLC (0.08%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own iCAD stock include Andy Sassine, R Scott Areglado and Stacey M Stevens.
View institutional ownership trends for iCAD
.

Which institutional investors are selling iCAD stock?

ICAD stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC. Company insiders that have sold iCAD company stock in the last year include Andy Sassine, R Scott Areglado, and Stacey M Stevens.
View insider buying and selling activity for iCAD
.

Which institutional investors are buying iCAD stock?

ICAD stock was purchased by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc., and BNP Paribas Arbitrage SA.
View insider buying and selling activity for iCAD
.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $9.76.

How big of a company is iCAD?

iCAD has a market capitalization of $223.51 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. iCAD employs 135 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.